Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry.

Alzheimer's disease CSF LC–HRMS Quantitative proteomics SP3 Tau protein brain soluble fraction

Journal

European journal of mass spectrometry (Chichester, England)
ISSN: 1751-6838
Titre abrégé: Eur J Mass Spectrom (Chichester)
Pays: England
ID NLM: 101124748

Informations de publication

Date de publication:
23 Jan 2024
Historique:
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: aheadofprint

Résumé

Tubulin-associated unit (tau) has an important role in the pathogenesis and the diagnosis of Alzheimer's disease (AD) and other tauopathies. In view of the diversity of tau proteoforms, antibody-free methods represent a good approach for unbiased quantification. We adapted and evaluated the single-pot, solid-phase-enhanced sample-preparation (SP3) protocol for antibody-free extraction of the tau protein in cerebro-spinal fluid (CSF) mimic and in human brain. A total of 13 non-modified peptides were quantified by high-resolution mass spectrometry (HRMS) after digestion of tau by trypsin. We significantly improved the basic SP3 protocol by carefully optimizing the organic solvents and incubation time for tau binding, as well as the digestion step for the release directly from the SP3 beads of the 13 tau peptides. These optimizations proved to be primarily beneficial for the most hydrophilic tau peptides, increasing the sequence coverage of recombinant tau. Mean recovery in CSF mimic of the 13 non-modified peptides was of 53%, with LODs ranging from 0.75 to 10 ng/mL. Next, we tested the optimized SP3 protocol on pathological tau extracted from the soluble fraction from an AD brain sample (middle frontal gyrus). We could successfully identify and quantify biologically relevant tau peptides including representative peptides of two isoforms and two phospho-peptides (pTau217 and pTau181).

Identifiants

pubmed: 38258392
doi: 10.1177/14690667231218912
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

14690667231218912

Auteurs

Chloé Jacquemin (C)

Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France.

Nicolas Villain (N)

Department of Neurology, Institute of Memory and Alzheimer's Disease, Assistance Publique - Hopitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.

Rita Azevedo (R)

Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France.

Susana Boluda (S)

Department of Neuropathology Raymond Escourolle, Assistance Publique - Hôpitaux de Paris (AP-HP) Sorbonne, Pitié-Salpêtrière, Paris, France.

Etienne A Thévenot (EA)

Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France.

François Fenaille (F)

Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France.

Foudil Lamari (F)

Service de Biochimie Métabolique, AP-HP Sorbonne, Paris Brain Institute (ICM) Inserm - Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.

François Becher (F)

Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France.

Classifications MeSH